|
|
|
Volumn 11, Issue 6, 1997, Pages 819-820
|
|
Vaccine therapy in early HIV-1 infection using a recombinant canarypox virus expressing gp160(MN) (ALVAC-HIV): A double-blind controlled randomized study of safety and immunogenicity [1]
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CD4 ANTIGEN;
GLYCOPROTEIN GP 160;
HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;
HUMAN IMMUNODEFICIENCY VIRUS VACCINE;
RECOMBINANT VACCINE;
ANTIBODY PRODUCTION;
ANTIBODY RESPONSE;
CLINICAL ARTICLE;
CLINICAL EXAMINATION;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CYTOTOXIC T LYMPHOCYTE;
DIARRHEA;
DOUBLE BLIND PROCEDURE;
DRUG SAFETY;
ENZYME LINKED IMMUNOSORBENT ASSAY;
FATIGUE;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
IMMUNE RESPONSE;
IMMUNIZATION;
IMMUNOGENICITY;
INTRAMUSCULAR DRUG ADMINISTRATION;
LETTER;
NAUSEA;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL;
SWEAT;
AVIPOXVIRUS;
CONSUMER PRODUCT SAFETY;
DOUBLE-BLIND METHOD;
GENETIC VECTORS;
HIV ANTIBODIES;
HIV CORE PROTEIN P24;
HIV ENVELOPE PROTEIN GP160;
HIV INFECTIONS;
HUMANS;
IMMUNOGENETICS;
IMMUNOTHERAPY, ACTIVE;
RECOMBINATION, GENETIC;
VACCINES, SYNTHETIC;
VIRAL LOAD;
VIRAL VACCINES;
|
|
EID: 0030896310
PISSN: 02699370
EISSN: None
Source Type: Journal
DOI: None Document Type: Letter |
|
Times cited : (30)
|
|
References (13)
|
